Adjust Text Size:change font sizechange font sizechange font sizechange font sizechange font sizechange font size

Our Research

We're funding nearly $5 million in scientific research to solve, treat and end Parkinson's.

Learn More

Join our Team

What's your passion? Put it to use for Parkinson's with PDF Champions, our grassroots fundraising program.

Join Us

We Need You

People with Parkinson's are key partners in our work to solve, treat and end the disease.

Learn More

A New Home for Parkinson's Science

An open access journal, enabling professionals and people with PD to access the latest research.

Learn More
       

Understanding PD Prevalence

Understanding how many people are living with PD is critical to advancing research and care. To address it, PDF is investing $250,000 in the PD Prevalence Project. 

Learn More 
Your Donations Make a Difference

Your support makes the research of Dr. Hess and Dr. Earhart possible, allowing us to learn about the role of genetics and the potential of exercise in Parkinson's.


Watch Our Video & Learn More

VIDEO: FDA Approves Nuplazid™ for Treatment of Psychosis in Parkinson’s

May 3, 2016

The Parkinson’s Disease Foundation (PDF) alerts the community that pimavanserin (Nuplazid™) has been approved by the US Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The drug’s manufacturer, Acadia Pharmaceuticals Inc., announced the approval on April 29. Pimavanserin is the first drug indicated specifically to treat symptoms of psychosis in Parkinson’s. See this article, and a new video from Dr. James Beck, Vice President, Scientific Affairs at PDF, to learn more.

Learn More

View All News

PDF Research: Conference on Non-Pharma Ways to Maintain Cognition

Friday, June 3 (Chicago, IL)

The conference, led by Jennifer Goldman, M.D., M.S., of the PDF Research Center at Rush University Medical Center, Chicago, IL, is funded as part of the PDF Community Choice Research Awards, which seek insight from the patient community about its priorities for research. PDF is gathering leaders in Parkinson’s as well as specialists from related areas to assess where we are in understanding and treating cognition, and what needs to be done to move the field forward.

Click Here to Learn More

Community Events

View All Upcoming Events = PDF Sponsored Events